

Patrizio Armeni

ASSOCIATE PROFESSOR OF PRACTICE

Health Economics and HTA

PATRIZIO.ARmeni@UNIBOCCONI.IT

Biography

Patrizio Armeni is Associate Professor of Practice in Government, Health and Not for Profit at SDA Bocconi School of Management.

Patrizio's collaboration with SDA Bocconi started in 2009. He has gradually widened the scope of his research and teaching which began with the Osservatorio Farmaci (Pharmaceutical Observatory) and went on to include, over time, other research areas related to public management, with a particular focus on the healthcare sector. His knowledge of healthcare organizations has awakened his interest in studying organizational behaviors of individuals and teams and led him to adopt an educational approach based on the daily practice of ethical principles in the workplace (leadership in practice).

He has directed various executive programs for employees of pharmaceutical and medical device companies and has coordinated several sponsored educational programs dedicated to physicians and other healthcare and public sector professionals. He supervises a category of open market courses including programs dedicated to the interaction between the national health service and technology providers (pharma, medical devices, services). He also teaches «Public Management» and «Innovation and competition in life science» at undergraduate level, and several courses on national and international master programs: «Economics of healthcare organizations», «Pharmaceutical policy», «Economic Evaluations - advanced» and «Evidence-based health policy evaluation», «Policy Evaluation».

He coordinates the research area «Health Economics & HTA» at CERGAS (Center for Research on Health and Social Care Management) at SDA Bocconi. His current research activity is focused on three themes: 1) economic evaluations of healthcare technologies (cost-effectiveness, cost-utility and budget impact analysis) and related methodological developments founded on the pillar of value-based healthcare; 2) analysis and support for policymakers for public policy design and implementation; 3) analysis of pharmaceutical and health technology markets in terms of performance, innovation and reaction to public policies. He has published several articles in international peer-reviewed journals and is the author of a number of chapters in monographic works. Since 2009 he has authored the chapter on healthcare expenditure in the OASI (Observatory on Healthcare Organizations and Policies in Italy) report, the leading annual Italian publication on issues relating to the healthcare system. He is member of the editorial board of the OASI report. Since 2020 he was appointed as director of operation of the newborn "LIFT" Lab dedicated to the convergence between digital innovation and life sciences.

Patrizio's production and diffusion of knowledge is coupled with frequent participation as a speaker in international and national congresses and conferences. He serves as an expert on advisory boards for companies operating in the pharmaceutical / medical.

Teaching domains

Economic Evaluations of Drugs

Health Technology Assessment

Policy Impact Analysis

Real-World Data and Real-World Evidence

Self-Leadership

ARTICLES IN SCHOLARLY JOURNALS

ROGNONI C., LORUSSO D., COSTA F., ARMENI P.

Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy

Advances in Therapy, 2024, vol.41, no. 4, pp.1385-1400

ARSENAULT C., LEWIS T. P., KAPOOR N. R., OKIRO E. A., LESLIE H. H., ARMENI P., JARHYAN P., DOUBOVA S. V., WRIGHT K. D., ARYAL A., KOUNNAVONG S., MOHAN S., ODIPO E., LEE H., SHIN J., AYELE W., MEDINA-RANILLA J., ESPINOZA-PAJUELO L., DERSEH MEBRATIE A., GARCÍA ELORRIO E., MAZZONI A., OH J., STEELFISHER G. K., TARRICONE R., KRUK M. E.

Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries

The Lancet Global Health, 2024, vol.12, no. 1, pp.e156-e165

ARMENI P., MEREGAGLIA M., BORSOI L., CALLEA G., TORBICA A., BENAZZO F., TARRICONE R.

Collecting Physicians' Preferences on Medical Devices: Are We Doing It Right? Evidence from Italian Orthopedists Using 2 Different Stated Preference Methods

Medical Decision Making, 2023, vol.43, no. 7-8, pp.886-900

JOMMI C., BERTOLANI A., ARMENI P., COSTA F., OTTO M.

Pharmaceutical pricing and managed entry agreements: an exploratory study on future perspectives in Europe

Health Policy and Technology, 2023, vol.12, no. 2, pp.100771

ROGNONI C., SEGANTIN G., SCARSINI R., VALGIMIGLI M., LOIZZI F., COSTA F., ARMENI P.

Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention

Expert Review of Pharmacoeconomics & Outcomes Research, 2023, vol.23, no. 9, pp.1101-1111

ROGNONI C., MILANO C., HEFFLER E., BONINI M., BRUSSINO L., CARPAGNANO G. E., RICCIARDOLO F. L. M., COSTA F., ARMENI P.

Economic impact of a more extensive use of FENO testing on the Italian population with asthma

Respiratory Research, 2023, vol.24, pp.147

TARANTOLA A., OTTO M., ARMENI P., COSTA F., MALANDRINI F., JOMMI C.

Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case

Journal of Pharmaceutical Policy and Practice, 2023, vol.16, no. 1, pp.67

ROGNONI C., FALIVENA C., COSTA F., ARMENI P.

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy

PharmacoEconomics, 2023, vol.41, pp.209-225

BORSOI L., ARMENI P., BRANDI M. L.

Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis

Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2023, vol.10, no. 1, pp.1-11

GISONDI P., GEAT D., ARMENI P., BELLINATO F., MAURELLI M., GIROLOMONI G.

Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis

Expert Opinion on Biological Therapy, 2022, vol.22, no. 12, pp.1579-1584

FORNARO G., ARMENI P., ALBERA A., BARBARA M.

The Value of Hearing Aids for the Italian NHS: A Cost-utility Analysis

Otology & Neurotology Open (ONO), 2022, vol.2, no. 4, pp.e018

FEDERICI C. B., ROGNONI C., COSTA F., ARMENI P., CROVATO E., BELLUCCI S.

Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma

Clinical Therapeutics, 2022, vol.44, no. 11, pp.1480-1493

ARMENI P., POLAT I., DE ROSSI L., DIAFERIA L., MEREGALLI S., GATTI A.

Digital Twins in Healthcare: Is It the Beginning of a New Era of Evidence-Based Medicine? A Critical Review

Journal of Personalized Medicine, 2022, vol.12, no. 8, pp.1255

BORSOI L., ARMENI P., DONIN G., COSTA F., FERINI-STRAMBI L.

The invisible costs of obstructive sleep apnea (OSA): Systematic review and cost-of-illness analysis

Plos One, 2022, vol.17, no. 5, pp.e0268677

JOMMI C., ARMENI P., COSTA F., ALBERTI C., BANDELLO F., BORDONARO R., CAPRODOSSI A., DI MAIO M., GAUDIOSO A., GIULIANI G., LANGELLA R., MARATA A. M., PATARNELLO F., PINTO C., RASI G., VILLA F.

Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement)

Recenti Progressi in Medicina, 2021, vol.112, no. 11, pp.749-756

TARRICONE R., AMATUCCI F., ARMENI P., BANKS H., BORSOI L., CALLEA G., CIANI O., COSTA F., FEDERICI C. B., TORBICA A., MARLETTA M.

Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies

Health Policy, 2021, vol.125, no. 5, pp.602-608

ARMENI P., CAVAZZA M., XOXI E., TARUSCIO D., KODRA Y.

Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal

International Journal of Environmental Research and Public Health, 2021, vol.18, no. 3, pp.1101

JOMMI C., ARMENI P., BERTOLANI A., COSTA F., OTTO M.

The future of Funds for Innovative Medicines: results from a Delphi Study

Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2021, vol.8, pp.22-28

KODRA Y., CAVAZZA M., DE SANTIS M., GUALA A., LIVERANI M., ARMENI P., MASINI M., TARUSCIO D.

Social Economic Costs, Health-Related Quality of Life and Disability in Patients with Cri Du Chat Syndrome

International Journal of Environmental Research and Public Health, 2020, vol.17, no. 16, pp.5951

ARMENI P., BORSOI L., FORNARO G., JOMMI C., COLOMBO N., COSTA F.

Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service

Clinical Therapeutics, 2020, vol.42, no. 7, pp.1192-1209

ARMENI P., BORSOI L., FORNARO G., JOMMI C., GROSSI F., COSTA F.

Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service

Clinical Therapeutics, 2020, vol.42, no. 5, pp.830-847

GALLONE G., ARMENI P., VERHEYE S., AGOSTONI P., TIMMERS L., CAMPO G., IELASI A., SGURA F., TARANTINI G., ROSSEEL L., ZIVELONGHI C., LEENDERS G., STELLA P., TEBALDI M., TESPILI M., D'AMICO G., BALDETTI L., PONTICELLI F., COLOMBO A., GIANNINI F.

Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients

European Heart Journal – Quality of Care and Clinical Outcomes, January, 2020, vol.6, no. 1, pp.32-40

ROGNONI C., ARMENI P., TARRICONE R., DONIN G.

Cost-benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet

Clinical Therapeutics, 2020, vol.42, no. 1, pp.60-75.e7

JOMMI C., ARMENI P., COSTA F., BERTOLANI A., OTTO M.

Implementation of Value-based Pricing for Medicines

Clinical Therapeutics, 2020, vol.42, no. 1, pp.15-24

BENITO-GONZÁLEZ T., ARMENI P., ESTÉVEZ-LOUREIRO R., VILLABLANCA P. A., IGLESIAS-GÁRRIZ I., MINGUITO C., GARROTE C., DE PRADO A. P., TUNDIDOR-SANZ E., GUALIS J., FERNÁNDEZ-VÁZQUEZ F.

Percutaneous Mitral Valve Repair Vs. Stand-Alone Medical Therapy in Patients with Functional Mitral Regurgitation and Heart Failure

Cardiovascular Revascularization Medicine, 2020, vol.21, no. 1, pp.52-60

TARRICONE R., CUCCINIELLO M., ARMENI P., PETRACCA F., DESOUZA K. C., HALL L. K., KEEFE D.

Mobile Health Divide Between Clinicians and Patients in Cancer Care: Results From a Cross-Sectional International Survey

JMIR mHealth and uHealth, 2019, vol.7, no. 9, pp.e13584

ARMENI P., COMPAGNI A., TASSELLI S.

When peers count: The effects on integrated type II diabetes care of communication within general practitioner-only subgroups in interprofessional primary care teams

Health Care Management Review, 2019, vol.44, no. 1, pp.67-78

GIANNINI C., D'ASCENZO F., FIORELLI F., SPONTONI P., SWAANS M. J., VELAZQUEZ E. J., ARMENI P., ADAMO M., DE CARLO M., PETRONIO A. S.

A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients

ESC Heart Failure, 2018, vol.5, no. 6, pp.1150-1158

JOMMI C., ARMENI P., BATTISTA M., DI PROCOLO P., CONTE G., RONCO C., COZZOLINO M., COSTANZO A. M., DI LUZIO PAPANATTI U., CONCAS G., REMUZZI G.

The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study

PharmacoEconomics – Open, 2018, vol.2, no. 4, pp.459-467

OTTO M., ARMENI P., JOMMI C.

Variations in non-prescription drug consumption and expenditure: Determinants and policy implications

Health Policy, 2018, vol.122, no. 6, pp.614-620

ARMENI P., TORBICA A., TARRICONE R., DRUMMOND M.

Diffusion without Evidence: A Study on High-Risk Medical Devices

Value in Health, 2018, vol.21, pp.S175

CALLEA G., ARMENI P., MARSILIO M., JOMMI C., TARRICONE R.

The impact of HTA and procurement practices on the selection and prices of medical devices

Social Science & Medicine, 2017, vol.174, pp.89-95

BURQOL-RD RESEARCH NETWORK, CAVAZZA M., KODRA Y., ARMENI P., DE SANTIS M., LÓPEZ-BASTIDA J., LINERTOVÁ R., OLIVA-MORENO J., SERRANO-AGUILAR P., POSADA-DE-LA-PAZ M., TARUSCIO D., SCHIEPPATI A., ISKROV G., PÉNTEK M., VON DER SCHULENBURG J. M. G., KANAVOS P., CHEVREUL K., PERSSON U., FATTORE G.

Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe

The European Journal of Health Economics, 2016, vol.17, no. S1, pp.19-29

BURQOL-RD RESEARCH NETWORK, FATTORE G., CAVAZZA M., KODRA Y., ARMENI P., DE SANTIS M., LÓPEZ-BASTIDA J., LINERTOVÁ R., OLIVA-MORENO J., SERRANO-AGUILAR P., POSADA-DE-LA-PAZ M., TARUSCIO D., SCHIEPPATI A., ISKROV G., GULÁCSI L., VON DER SCHULENBURG J. M. G., KANAVOS P., CHEVREUL K., PERSSON U.

Social/economic costs and quality of life in patients with haemophilia in Europe

The European Journal of Health Economics, 2016, vol.17, no. S1, pp.53-65

CIANI O., ARMENI P., BOSCOLO P. R., CAVAZZA M., JOMMI C., TARRICONE R.

De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making

Health Policy and Technology, 2016, vol.5, no. 1, pp.47-64

ARMENI P., COSTA F., OTTO M., AMOROSO N., JOMMI C.

La rendicontazione e la remunerazione dei farmaci

Mecosan, 2016, vol.25, no. 98, pp.61-82

ARMENI P., CARBONE C., FENECH L., LONGO F., PETRACCA F., RICCI A., SOMMARIVA S.

La sanità può cambiare anche a costo zero. Cinque interventi: geografia dei servizi, innovazione, processi di fusione, integrazione dei consumi privati e gestione del personale

Economia & Management, 2016, no. 3, pp.56-61

ARMENI P., BOSCOLO P., TARRICONE R., CAPODANNO D., MAGGIONI A., GRASSO C., MAISANO F.

Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation

International Journal of Cardiology, 2016, vol.209, pp.153-160

ARMENI P., JOMMI C., OTTO M.

The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study

The European Journal of Health Economics, 2016, vol.17, no. 8, pp.963-977

ARMENI P., TARRICONE R., BOSCOLO P.

What type of clinical evidence is needed to assess medical devices?

European Respiratory Review, 2016, vol.25, no. 141, pp.259-265

ARMENI P., GONZALEZ F., FINCH A., BOSCOLO P., TARRICONE R.

Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review

Expert Review of Medical Devices, 2015, vol.12, no. 4, pp.471-485

ARMENI P., COMPAGNI A., LONGO F.

Multi-professional primary care units: what affects the clinical performance of Italian general practitioners?

Medical Care Research and Review, 2014, vol.71, no. 4, pp.315-336

ARMENI P., OTTO M., JOMMI C.

PHP3 the simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study

Value in Health, 2014, vol.17, no. 7, pp.A405

KODRA Y., CAVAZZA M., SCHIEPPATI A., DE SANTIS M., ARMENI P., ARCIERI R., CALIZZANI G., FATTORE G., MANZOLI L., MANTOVANI L., TARUSCIO D.

The social burden and quality of life of patients with haemophilia in Italy

Blood Transfusion, 2014, vol.12, no. S3, pp.s567-s575

GHISLANDI S., ARMENI P., JOMMI C.

The impact of generic reference pricing in Italy, a decade on

The European Journal of Health Economics, 2013, vol.14, no. 6, pp.959-969

ARMENI P., CIANI O., VELLA V.

Il settore dei dispositivi medici in Italia. L'impatto delle politiche pubbliche sulle performance delle imprese

Azienda Pubblica, 2012, no. 2, pp.217-238

JOMMI C., OTTO M., ARMENI P., DE LUCA C.

Market access management by pharmaceutical companies in a complex environment: The Italian case study

Journal of Medical Marketing, 2012, vol.12, no. 2, pp.93-103

ARMENI P., CIANI O., TARRICONE R., PALLA I., PIEROTTI F., TURCHETTI G.

PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani

Mecosan, 2011, vol.79, pp.9-22

TARRICONE R., CAVALLO M. C., CIANI O., ARMENI P., VELLA V. A.

I Dispositivi medici in Italia: un settore, tanti mercati

Mecosan, 2010, vol.76, pp.65-81

CONTRIBUTION TO CHAPTERS, BOOKS OR RESEARCH MONOGRAPHS

ARMENI P., CALLEA G., COSTA F., MALANDRINI F., OTTO M., SEGANTIN G., SIRENA P., TARRICONE R.

Il payback come misura di contenimento della spesa per farmaci e dispositivi medici in *Rapporto OASI 2023*

CERGAS (Eds),Egea, chap. 17, pp.651-698, 2023

ARMENI P., COSTA F., JOMMI C., MALANDRINI F., OTTO M., TARANTOLA A.

L'evoluzione del finanziamento dei farmaci in Italia in *Rapporto OASI 2023*

CERGAS (Eds),Egea, chap. 8, pp.317-354, 2023

ARMENI P., COSTA F., MILANO C., SEGANTIN G.

Digitalizzazione nelle tecnologie per la salute: impatto sui livelli di governo del SSN in *Rapporto OASI 2022*

CERGAS (Eds),Egea, chap. 18, pp.673-726, 2022

ARMENI P., BORSOI L., NOTARNICOLA E., ROTA S.

La spesa sanitaria: composizione ed evoluzione nella prospettiva nazionale, regionale ed aziendale in *Rapporto OASI 2022*

CERGAS (Eds),Egea, chap. 3, pp.93-150, 2022

ARMENI P., BERTOLANI A., BORSOI L., COSTA F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2021*

CERGAS (Eds),Egea, chap. 3, pp.117-173, 2021

ARMENI P., BERTOLANI A., BORSOI L., COSTA F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2020*

CERGAS (Eds),Egea, chap. 3, pp.109-162, 2020

ARMENI P., COSTA F., CALLEA G., BORSOI L., CAVALLO M. C., CIANI O., FEDERICI C. B., TARRICONE R., TORBICA A.

Dinamiche economiche e performance del settore dei dispositivi medici in Italia in *Rapporto OASI 2019*

CERGAS (Eds),Egea, chap. 17, pp.643-680, 2019

ARMENI P., BORSOI L., BERTOLANI A., COSTA F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2019*

CERGAS (Eds),Egea, chap. 3, pp.99-152, 2019

ARMENI P., BERTOLANI A., OTTO M.

Le previsioni sulla spesa e i consumi di farmaci senza obbligo di prescrizione: il triennio 2019-2021 in *Numero e indici dell'automedicazione*

Centro Studi Assosalute (Eds),Federchimica Assosalute, chap. 4, pp.161-176, 2019

ARMENI P., BERTOLANI A., BORSOI L., COSTA F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2018*

CERGAS (Eds),Egea, chap. 3, pp.119-178, 2018

ARMENI P., BERTOLANI A., OTTO M.

Le previsioni sulla spesa e i consumi di farmaci senza obbligo di prescrizione: il triennio 2018-2020 in *Numeri e indici dell'automedicazione*

Centro Studi Assosalute (Eds),Federchimica Assosalute, chap. 4, pp.161-176, 2018

ARMENI P., BERTOLANI A., COSTA F., OTTO M., JOMMI C.

L'acquisto di farmaci in Italia: l'effetto di approcci selettivi in *Rapporto OASI 2018*

CERGAS (Eds),Egea, chap. 17, pp.611-648, 2018

VERONESI U., MAURI M., DEL VECCHIO M., ARMENI P., ESPOSITO V., PEZZILLO IACONO M., MERCURIO L., POLIMENI J.

Myth #1: The Healthcare System Is Failing in *The Myths of Health Care - Towards New Models of Leadership and Management in the Healthcare Sector*

P. Adinolfi, E. Borgonovi (Eds),Springer, chap. 4, pp.43-66, 2018

ARMENI P., BOSCOLO P. R., CALLEA G., CAVALLO M. C., CIANI O., COSTA F., GHISLANDI S., TARRICONE R., TORBICA A.

Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci in *Rapporto OASI 2018*

CERGAS (Eds),Egea, chap. 15, pp.567-586, 2018

ARMENI P., COSTA F.

Valutare i costi dell'osteoporosi e dei relativi interventi: panoramica sui possibili approcci in *Monografia n. 2 - Osteoporosi e fratture da fragilità - Aspetti clinici, economici e medico legali*

P.Armeni, F.Costa, F.Donelli (Eds),Pacini Editore - Medicina, pp.5-19, 2018

ARMENI P., LECCI F., RICCI A., VENDRAMINI E.

Starve the beast to let it back to the iron cage: do budget constraints increase isomorphism? in *Sviluppo, sostenibilità e competitività delle aziende. Il contributo degli economisti aziendali*

E. Borgonovi, G. Aiello, A. M. Fellegara (Eds),Il Mulino, pp.207-221, 2017

ARMENI P., FURNARI A., COSTA F.

Il confronto dei sistemi sanitari in una prospettiva internazionale in *Rapporto OASI 2017. Osservatorio sulle aziende e sul sistema sanitario italiano*

CERGAS (Eds),Egea, pp.89-127, 2017

ARMENI P., BERTOLANI A., COSTA F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2017*

CERGAS (Eds),Egea, chap. 5, pp.207-255, 2017

ARMENI P., BERTOLANI A., JOMMI C., OTTO M.

Le previsioni sulla spesa e i consumi di farmaci senza obbligo di prescrizione: il triennio 2017-2019 in *Numeri e indici dell'automedicazione*

Centro Studi Assosalute (Eds),Federchimica Assosalute, chap. 4, pp.159-174, 2017

DEL VECCHIO M., VERONESI U., MAURI M., ARMENI P., ESPOSITO V., PEZZILLO IACONO M., MERCURIO L., POLIMENI J.

Myth #1: The Healthcare System Is Failing in *The Myths of Health Care. Towards New Models of Leadership and Management in the Healthcare Sector*

P.Adinolfi, E.Borgonovi (Eds),Springer, chap. 4, pp.43-66, 2017

ARMENI P., BERTOLANI A., COSTA F., JOMMI C., OTTO M.

Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull'adozione di forme alternative di distribuzione dei farmaci in *Rapporto OASI 2017*

CERGAS (Eds),Egea, chap. 14, pp.503-533, 2017

TARRICONE R., CIANI O., AMATUCCI F., ARMENI P., BORSOI L., CALLEA G., COSTA F., FEDERICI C., TORBICA A., MARLETTA M.

Programma Nazionale HTA per dispositivi medici: prove tecniche di implementazione in *Rapporto OASI 2017*

CERGAS (Eds),Egea, chap. 15, pp.535-553, 2017

ARMENI P., AMOROSO N., COSTA F., JOMMI C., OTTO M.

Governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento in *Rapporto OASI 2016*
CERGAS (Eds),Egea, pp.339-366, 2016

ARMENI P., FURNARI A., COSTA F.

Il confronto dei sistemi sanitari in una prospettiva internazionale in *Rapporto Oasi 2016. Osservatorio sulle aziende e sul sistema sanitario italiano*
CERGAS (Eds),Egea, pp.33-81, 2016

ARMENI P., AMOROSO N., COSTA F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto Oasi 2016. Osservatorio sulle aziende e sul sistema sanitario italiano*
CERGAS (Eds),Egea, pp.155-200, 2016

ARMENI P., COSTA F., SOMMARIVA S.

Il confronto dei sistemi sanitari in una prospettiva internazionale in *Rapporto OASI 2015*
CERGAS (Eds),Egea, pp.27-72, 2015

ARMENI P., COSTA F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2015*
CERGAS (Eds),Egea, pp.143-183, 2015

ARMENI P., COSTA F., FERRÉ F.

I settori contigui alla sanità: struttura e performance delle imprese farmaceutiche, di dispositivi medici e delle farmacie in Italia in *Rapporto OASI 2014 - Osservatorio sulle Aziende e sul Sistema sanitario italiano*
CERGAS (Eds),Egea, pp.241-293, 2014

ARMENI P., FERRE¹ F., SOMMARIVA S.

Il confronto dei sistemi sanitari in una prospettiva internazionale in *Rapporto OASI 2014 - Osservatorio sulle Aziende e sul Sistema sanitario italiano*
CERGAS (Eds),Egea, pp.1-41, 2014

ARMENI P., CALLEA G., TARRICONE R.

L'adozione dell'innovazione tecnologica da parte degli ospedali italiani: un'analisi dei fattori endogeni in *Rapporto OASI 2014 - Osservatorio sulle Aziende e sul Sistema sanitario italiano*
CERGAS (Eds),Egea, chap. 11, pp.381-400, 2014

ARMENI P., FERRÉ F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2014 - Osservatorio sulle Aziende e sul Sistema sanitario italiano*
CERGAS (Eds),Egea, pp.141-181, 2014

ARMENI P., FERRÉ F., LORENZONI L., SOMMARIVA S.

Il confronto dei sistemi sanitari in una prospettiva internazionale in *Rapporto OASI 2013. L'aziendalizzazione della sanità in Italia.*
CERGAS (Eds),Egea, pp.27-87, 2013

ARMENI P., FERRÉ F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2013. L'aziendalizzazione della Sanità in Italia*
CERGAS (Eds),Egea, pp.183-221, 2013

ARMENI P., FERRÉ F.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2012. L'aziendalizzazione della Sanità in Italia*
E.Cantù (Eds),Egea, pp.109-165, 2012

JOMMI C., ARMENI P., DE LUCA C., OTTO M., VELLA V.

Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa in *Rapporto OASI 2011. L'aziendalizzazione della Sanità in Italia*
E.Cantù (Eds),Egea, pp.259-296, 2011

ARMENI P.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2011. L'aziendalizzazione della Sanità in Italia*
E.Cantù(Ed), Egea, pp.105-172, 2011

ARMENI P.

La spesa sanitaria: composizione ed evoluzione in *Rapporto Oasi 2010. L'aziendalizzazione della Sanità in Italia*
E.Cantù(Ed), Egea, pp.95-166, 2010

ARMENI P.

La spesa sanitaria: composizione ed evoluzione in *Rapporto OASI 2009. L'aziendalizzazione della Sanità in Italia*
E.Cantù(Ed), Egea, chap. 3, pp.87-155, 2009

ARMENI P.

The Sovereign Wealth Funds in *The Great Financial Crisis*
Rainer Masera(Ed), Bancaria Editrice, chap. 6, 2009

ARTICLES IN NATIONAL/INTERNATIONAL NEWSPAPERS

ARMENI P., COSTA F., OTTO M.

Manovra/ Legge di bilancio e modalità di distribuzione dei farmaci: luci e ombre dei potenziali impatti
Sanità. Il Sole 24 ore, 3 November, 2023

ARMENI P., COSTA F.

Farmaci maturi e il prezzo dei ribassi. Perché l'ossessione del risparmio sortisce l'effetto opposto
Sanità. Il Sole 24 ore, 14 January, 2022

ARMENI P., BERTOLANI A., COSTA F., OTTO M., JOMMI C.

Tetti alla farmaceutica e sostenibilità: il risultato è possibile, ma la strada è giusta?
Sanità. Il Sole 24 ore, 23 March, 2021

ARMENI P., BORSOI L., COSTA F.

Il finanziamento dei farmaci che escono dal Fondo innovativi
Sanità. Il Sole 24 ore, 26 January, 2021

JOMMI C., ARMENI P., BERTOLANI A., COSTA F., OTTO M.

Il futuro della politica del farmaco in Italia: l'opinione degli stakeholder
Sanità. Il Sole 24 ore, 1 April, 2020

ARMENI P., BERTOLANI A., COSTA F., OTTO M., JOMMI C.

Farmaci Ssn, gli acquisti diretti 60% della spesa. Il monito: «Rivedere il sistema dei tetti»
Sanità. Il Sole 24 ore, 29 October, 2019

ARMENI P., BERTOLANI A., COSTA F., OTTO M., JOMMI C.

Value Based Pricing per i farmaci: chimera o realtà?
Sanità. Il Sole 24 ore, 29 October, 2019

ARMENI P., COSTA F., JOMMI C.

Il valore della farmacologia innovativa. Come si misura il costo dei farmaci
Il Sole 24 Ore, 2 July, 2019

JOMMI C., ARMENI P., COSTA F., BERTOLANI A., OTTO M.

Trasparenza del prezzo dei farmaci: il punto sulla lettera della Salute all'Oms
Sanità. Il Sole 24 ore, 2 April, 2019

JOMMI C., ARMENI P., COSTA F., BERTOLANI A., OTTO M.

Nuova governance farmaci/ Luci e ombre tra tetti di spesa, definizione dei prezzi e payback
Sanità. Il Sole 24 ore, 19 December, 2018

ARMENI P., COSTA F.

Farmaci e rimborsabilità debole: i legami mancanti per una tutela equa del diritto alle terapie

Sanità. Il Sole 24 ore, 25 October, 2018

ARMENI P., BERTOLANI A., COSTA F., OTTO M., JOMMI C.

Rapporto Oasi Cergas-Bocconi/ Politiche del farmaco e impatto sulla spesa: gli effetti del decentramento nel Ssn con focus sulle forme alternative di distribuzione

Sanità. Il Sole 24 ore, 16 March, 2018

ARMENI P., BERTOLANI A., COSTA F.

La spesa sanitaria: composizione ed evoluzione tra nuovi equilibri e disomogeneità strutturali

Sanità. Il Sole 24 ore, 28 February, 2018

ARMENI P., FENECH L., FURNARI A., LONGO F., PETRACCA F., RICCI A.

Rapporto Oasi 2016/ Un Ssn in salute ma diseguale: 2,7 milioni di anziani non autosufficienti chiedono assistenza

Sanità. Il Sole 24 ore, 14 November, 2016

JOMMI C., OTTO M., ARMENI P., COSTA F.

Farmaci, excursus su 14 anni tra falsa insostenibilità e mix di spesa

Sanità. Il Sole 24 ore, 14 July, 2015

ARMENI P., FERRÉ F., SOMMARIVA S.

Oasi 2013: vizi e virtù di un Ssn risparmiato. Il nostro sistema è tra quelli che spendono meno e meglio

Sanità. Il Sole 24 ore, 17 February, 2014

ARTICLES UPON REQUEST/INVITATION

ARMENI P., COSTA F., JOMMI C.

Opportunità e sfide nelle terapie avanzate (ATMP). Prospettive di policy ed economiche

2019, Ematos, Italy

EDITORIALS IN JOURNAL

FEDERICI C. B., ARMENI P., CALLEA G.

A Value-based Revolution in Health Care: Perspectives, Challenges, and Emerging Approaches to Defining and Measuring the Value of Health Care Technologies

2020, Clinical Therapeutics

CUSUMANO N., OTTO M., ARMENI P., COSTA F., BERTOLANI A., JOMMI C.

La centralizzazione degli acquisti: riflessioni sulle performance del sistema

2019, Policy and Procurement in Healthcare, Italy

EDITORSHIP OF SPECIAL ISSUES

ARMENI P., CALLEA G., FEDERICI C. B.

Pharmacoeconomics, Outcomes, and Health Policy Update

2020, Clinical Therapeutics

OTHER IN JOURNALS

ARMENI P., MEREGAGLIA M., BORSOI L., TORBICA A., CALLEA G.

PMD16 What Factors Do Clinicians Value Most in Selecting Physician Preference Items? a Survey in Orthopedics Using Discrete Choice Experiment and Best-Worst Scaling

2021, Value in Health

PROCEEDINGS/PRESENTATIONS

ARMENI P., MEREGAGLIA M., BORSOI L., CALLEA G., TORBICA A., TARRICONE R.

Are physicians aware about their preferences when choosing a technology? Evidence from Italian orthopaedists using two different stated preference methods

Italian Health Economics Association (AIES), 26th Annual Conference, 2-3 December, 2021, Milano, Italy

BORSOI L., ARMENI P., COSTA F., DONIN G., FERINI-STRAMB L.

The Clinical and Economic Burden of Obstructive Sleep Apnea in Adults: a Cost-of Illness Analysis in Italy

AIES (Italian Health Economics Association), 24th Annual Conference, 3-4 October, 2019, Pisa, Italy

ARMENI P., CUCCINIELLO M., PETRACCA F., TARRICONE R.

“Health technology assessment for eHealth solutions

IV European Congress on eCardiology and eHealth - November 9-10 2017, Berlin, Germany

ARMENI P., FEDERICI C. B., COSTA F., TARRICONE R., TORBICA A., CALLEA G.

Inclusion Of Learning Curve Effects In Economic Evaluations Of Medical Devices- Empirical Evidence For Hta

ISPOR 22nd Annual International Meeting - May 20-24, 2017, Boston, MA, United States of America

CALLEA G., GAUTIER L., ARMENI P., TARRICONE R.

The determinants of adoption and diffusion of innovative non-pharmaceutical technologies across life cycle: a systematic review of quantitative studies

ISPOR 22nd Annual International Meeting - May 20-24, 2017, Boston, MA, United States of America

ARMENI P., CUCCINIELLO M., PETRACCA F., TARRICONE R.

The digital divide between clinicians and patients. Results from an International e-Survey on mhealth in cancer and cancer supportive care”

21st Italian Health Economics Association (AIES) Annual Conference - November 3-4 2016, Bologna, Italy

ARMENI P., SENATORE P.

Overcoming HTA Hurdles through early collaboration between pharmaceutical companies companion diagnostic companies

ISPOR 19th Annual European Congress - October 29 - November 2, 2016, Wien, Austria

ARMENI P., AMOROSO N., COSTA F., JOMMI C., OTTO M.

Direct and mediated impacts of pharmaceutical policies on firms' performance

EUHEA 2016 Conference - July 13-16, 2016, Hamburg, Germany

ARMENI P., LECCI F., RICCI A., VENDRAMINI E.

Starve the beast to let it back to the iron cage: do budgetary constraints increase isomorphism?

XXXVII Convegno AIDEA - Settembre 10-12, 2015, Piacenza, Italy

ARMENI P., AMOROSO N., COSTA F., JOMMI C., OTTO M.

Direct and mediated impacts of pharmaceutical policies on firms' performance

iHEA Congress - July 12-15, 2015, Milano, Italy

CALLEA G., ARMENI P., TARRICONE R., CAVAZZA M., JOMMI C.

The determinants of uptake and diffusion of innovative health technologies. An empirical analysis

ISPOR 17th Annual European Congress - Health Care Use & Policy Studies - November 8-12 2014, Amsterdam, Netherlands (The)

ARMENI P., OTTO M., JOMMI C.

The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study

ISPOR 17th Annual European Congress - Health Care Use & Policy Studies - November 8-12 2014, Amsterdam, Netherlands (The)

CALLEA G., ARMENI P., TARRICONE R., CAVAZZA M., JOMMI C.

The determinants of uptake and diffusion of innovative health technologies

19th Italian Health Economics Association (AIES) Annual Conference - October 24-27, 2014, Venezia, Italy

ARMENI P., OTTO M., JOMMI C.

The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study

Italian Health Economics Association (AIES) 19th Annual Conference - The Financing Of Healthcare And Welfare Models In The Era Of Longevity - October 24-27, 2014, Venezia, Italy

MORANDO V., ARMENI P., TOZZI V., NASI G.

The role of Schools of Management to engender future leaders: a longitudinal study across MSc Italian students in health care management

British Academy of Management - September 9-12, 2014, Belfast, Ireland

CALLEA G., ARMENI P., TARRICONE R., CAVAZZA M., JOMMI C.

The determinants of uptake and diffusion of innovative health technologies. An empirical analysis

iHEA & ECHE Joint Congress, 10th World Congress in Health Economics - July 14-16, 2014, Dublin, Ireland

CALLEA G., GAUTIER L., ARMENI P., TARRICONE R.

The determinants of uptake and diffusion of innovative health technologies. A systematic literature review

18th Italian Health Economics Association (AIES) Annual Conference - November 22-23, 2013, Trento, Italy

TARRICONE R., ARMENI P., BOSCOLO P., CALLEA G., CAVAZZA M., CIANI O., JOMMI C., MARSILIO M., TORBICA A.

Do HTA practices and procurement policies impact expenditures for medical devices?

EHMA Annual Conference: What healthcare can we afford? Better, quicker, lower cost health services - June 26-28, 2013, Milano, Italy

RESEARCH REPORTS

ARMENI P., COSTA F., MALANDRINI F., TARANTOLA A.

Report OSFAR-Osservatorio Farmaci n.42

2022, CER GAS - SDA Bocconi, Milano, Italy

Grants & Honors

ViviSalute Award - ViviSalute Lombardia , 2016

Best Paper in Healthcare Management - AIES - Italian Health Economics Association , 2015

Best Paper by Young Researchers - AIES - Italian Health Economics Association , 2010
